Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257478 · ClinicalTrials.gov registry record · Phase 2
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00257478: Completed Phase 2 study, sponsored by Astellas Pharma.
NCT00257478 is a Phase 2 study that has completed, run by Astellas Pharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00257478, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
Interventions
- DRUG YM155
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00257478 record still lists
NCT00257478 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which YM155 is the first listed.
NCT00257478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00257478 about?
NCT00257478 is a clinical study titled "A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy". A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
What is the current status of trial NCT00257478?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00257478?
The interventions under investigation include: YM155 (DRUG).
Who is sponsoring clinical trial NCT00257478?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.